LB Pharmaceuticals (LBRX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on LB Pharmaceuticals (LBRX) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.00 of bullish evidence against -0.24 bearish.

LB Pharmaceuticals last closed at $34.62, -6.41% on the session.

Against the IVW growth benchmark the position is -7.33% over the forecast window.

The read is built from 12 underlying insights — 0 bullish and 12 bearish.

Agreement across those insights is 100%.

15 graded predictions for LBRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks LB Pharmaceuticals in the 25th percentile on return on equity, where 100 is best.

LB Pharmaceuticals is classified under Health Care / Pharmaceuticals, with a market capitalisation of $1.19B.

StockMap tracks LB Pharmaceuticals as the 50th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite LB Pharmaceuticals ranks 64th of 128 in the group, against a group median of -0.24.